Definitive chemoradiotherapy for oesophageal cancer - A promising start on an exciting journey

Clinical Oncology

Volumn 26, Issue 9, 2014, Pages 533-540

  Rackley, T ^a   Leong, T ^b   Foo, M ^b   Crosby, T ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Adenocarcinoma; Chemotherapy; Definitive chemoradiotherapy; Oesophageal cancer; Radiotherapy; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; ESOPHAGUS CANCER; GOLD STANDARD; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LOW ENERGY RADIATION; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; ADJUVANT THERAPY; ESOPHAGEAL NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; HUMANS; RADIOTHERAPY, ADJUVANT;

EID: 84905562570     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.06.001     Document Type: Article

References (83)

1. Health and Social Care Information Centre National oesophago-gastric cancer audit 2013.
2. Cancer Research UK. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/oesophagus/survival/.
3. Cooper J., Guo M., Herskovic A., et al. Chemoradiotherapy of locally advanced long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999, 17(281):1623-1627.
4. Banner R., Crosby T., Evans M. Call for a consensus treatment approach to the management of post-cricoid and upper oesophageal squamous cell carcinoma. Clin Oncol 2013, 25(3):215-216.
5. Enzinger P., Mayer R. Esophageal cancer. N Engl J Med 2003, 349(23):2241-2252.
6. Burmeister B., Smithers B., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6(9):659-668.
7. Van Hagen P., Hulshof M., van Lanschot J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366(22):2074-2084.
8. Esophageal and Esophagogastric Junction (excluding the proximal 5 cm of the stomach). NCCN guidelines, 2013.
9. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326(24):1593-1598.
10. Minsky B., Pajak T., Ginsberg R., et al. Phase III trial of combined-modality therapy for esophageal therapy: high-dose versus standard dose radiation therapy. J Clin Oncol 2002, 20(5):1167-1174.
11. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23(10):2310-2317.
12. Bedenne L., Michel P., Bouché O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25(10):1160-1168.
13. Gwynne S., Hurt C., Evans M., Holden C., Vout L., Crosby T. Definitive chemoradiation for oesophageal cancer - a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol 2011, 23(3):182-188.
14. Crosby T., Hurt C., Falk S., et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013, 14(7):627-637.
15. Teoh A., Chiu P., Yeung W., Liu S., Wong S., Ng E. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 2013, 24(1):165-171.
16. Coia L. Factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol 1997, 42(1):91-92.
17. Button M., Morgan C., Croydon E., Roberts S., Crosby T. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009, 73(3):818-823.
18. Denham J., Steigler A., Kilmurray J., et al. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. Clin Oncol 2003, 15(3):98-108.
19. Crosby T., Brewster A., Borley A., et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004, 90(1):70-75.
20. Gaspar L., Winter K., Kocha W., Coia L., Herskovic A., Graham M. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 2000, 88(5):988-995.
21. Urschel J., Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003, 185(6):538-543.
22. Fiorica F. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004, 53(7):925-930.
23. Gebski V., Burmeister B., Smithers B., Foo K., Zalcberg J., Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8(3):226-234.
24. Bonner J., Harari M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
25. RTOG0436. Available at: [Last accessed 12.11.13]. http://www.rtog.org/Portals/0/RTOG%20Broadcasts/Attachments/RTOG_0436_Invstg_Letter.pdf.
26. Medical Research Council Oesophageal Cancer Working Party Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727-1733.
27. Kelsen D., Ginsberg R., Pajak T., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339(27):1979-1984.
28. Gwynne S., Falk S., Gollins S., et al. Oesophageal chemoradiotherapy in the UK - current practice and future directions. Clin Oncol 2013, 25(6):368-377.
29. Dittler H.-J., Bollschweiler E., Siewert J. Value of endosonography in the preoperative staging of oesophageal carcinoma. Deutsch Med Wochenschr 1991, 116(15):561-566.
30. Konski A., Doss M., Milestone B., et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2005, 61(4):1123-1128.
31. Rice P., Crosby T., Roberts S. Variability of the carina-incisor distance as assessed by endoscopic ultrasound. Clin Oncol 2003, 15(7):383-385.
32. Kelly S., Harris K., Berry E., et al. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 2001, 49(4):534-539.
33. Duong C., Demitriou H., Weih L., et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2006, 33(7):759-769.
34. Moureau-Zabotto L., Touboul E., Lerouge D., et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 2005, 63(2):340-345.
35. MacManus M., Nestle U., Rosenzweig K., et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009, 91(1):85-94.
36. Vrieze O., Haustermans K., De Wever W., et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol 2004, 73(3):269-275.
37. Leong T., Everitt C., Yuen K., et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 2006, 78(3):254-261.
38. Onozawa M., Nihei K., Ishikura S., et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 2009, 92(2):266-269.
39. Gaur P., Sepesi B., Hofstetter W., et al. A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg 2010, 252(4):611-617.
40. Gao X.-S., Qiao X., Wu F., et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 2007, 67(2):389-396.
41. NEOSCOPE Radiotherapy treatment planning and delivery. Available at: [Last accessed 19.02.14]. http://www.rttrialsqa.org.uk/Neoscope/2013_05_21%20NeoSCOPE%20RT%20document%20v2.pdf.
42. Matzinger O., Gerber E., Bernstein Z., et al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 2009, 92(2):164-175.
43. Shridhar R., Chuong M., Weber J., et al. Outcomes of definitive or preoperative IMRT chemoradiation for esophageal cancer. J Radiat Oncol 2012, 1(4):347-354.
44. Fenkell L., Kaminsky I., Breen S., Huang S., Van Prooijen M., Ringash J. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiother Oncol 2008, 89(3):287-291.
45. Welsh J., Gomez D., Palmer M., et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 2011, 81(5):1336-1342.
46. Fukada J., Hanada T., Kawaguchi O., et al. Detection of esophageal fiducial marker displacement during radiation therapy with a 2-dimensional on-board imager: analysis of internal margin for esophageal cancer. Int J Radiat Oncol Biol Phys 2013, 85(4):991-998.
47. Zhao K., Liao Z., Bucci M., et al. Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. Radiother Oncol 2007, 84(3):283-289.
48. NRAG Developing a world class service for England 2007, Report to Ministers from National Radiotherapy Advisory Group.
49. Hawkins M., Aitken A., Hansen V., McNair H., Tait D. Set-up errors in radiotherapy for oesophageal cancers - is electronic portal imaging or conebeam more accurate?. Radiother Oncol 2011, 98(2):249-254.
50. Hawkins M., Brooks C., Hansen V., Aitken A., Tait D. Cone beam computed tomography-derived adaptive radiotherapy for radical treatment of esophageal cancer. Int J Radiat Oncol Biol Phys 2010, 77(2):378-383.
51. Bouchard M., McAleer M., Starkschall G. Impact of gastric filling on radiation dose delivered to gastroesophageal junction tumors. Int J Radiat Oncol Biol Phys 2010, 77(1):292-300.
52. Stahl M., Mariette C., Haustermans K., Cervantes A., Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(Suppl. 6):vi51-vi56.
53. Geh J., Bond S., Bentzen S., Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006, 78(3):236-244.
54. Burmeister B., Dickie G., Smithers B., Hodge R., Morton K. Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch Otolaryngol Head Neck Surg 2000, 126(2):205-208.
55. Safran H., DiPetrillo T., Akerman P., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, {HER2} overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol 2007, 67(2):405-409.
56. Graham M., Purdy J., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45(2):323-329.
57. Kim T., Cho K., Pyo H., et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 2005, 235(1):208-215.
58. Lee H., Vaporciyan A., Cox J., et al. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol 2003, 57(5):1317-1322.
59. Wang S., Liao Z., Vaporciyan A., et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2006, 64(3):692-699.
60. Hatakenaka M., Yonezawa M., Nonoshita T., et al. Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation. Int J Radiat Oncol Biol Phys 2012, 83(1):e67-e73.
61. Mukherjee S., Aston D., Minett M., Brewster A., Crosby T. The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers. Clin Oncol 2003, 15(3):115-120.
62. Fukada J., Shigematsu N., Takeuchi H., et al. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol 2013, 87(3):487-493.
63. Kirkpatrick J., van der Kogel A., Schultheiss T. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl.):S42-S49.
64. Lordick F., Ott K., Krause B.-J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8(9):797-805.
65. CALGB 80803. Randomized phase II trial of PET scan-directed combined modality therapy in esophageal cancer. Available at: [Last accessed 16.02.14]. http://www.utswmedicine.org/conditions-specialties/cancer/clinical-trials/fact-detail.html%3fprimarypurpose=10%26studyId=STU%20072012-091.
66. PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy. Available at: [Last accessed 16.02.14]. http://clinicaltrials.gov/ct2/show/NCT01333033?term=NCT01333033%26rank=1.
67. Sun Y.-S., Cui Y., Tang L., et al. Early evaluation of cancer response by a new functional biomarker: apparent diffusion coefficient. Am J Roentgenol 2011, 197(1):W23-W29.
68. Imanishi S., Shuto K., Aoyagi T., Kono T., Saito H. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma. Dig Surg 2013, 30(3):240-248.
69. Vandecaveye V., De Keyzer F., Hermans R. Diffusion-weighted magnetic resonance imaging in neck lymph adenopathy. Cancer Imaging 2008, 8:173-180.
70. Okumura H., Uchikado Y., Setoyama T., et al. Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg Today 2014, 44(3):421-428.
71. Miyazaki T., Kato H., Faried A., et al. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res 2005, 25(4):2749-2755.
72. Pasini F., de Manzoni G., Zanoni A., et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase. Cancer 2013, 119(5):939-945.
73. Ajani J., Walsh G., Komaki R., et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004, 100(11):2347-2354.
74. Swisher S., Ajani J., Komaki R., et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol 2003, 57(1):120-127.
75. Ajani J., Winter K., Komaki R., et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008, 26(28):4551-4556.
76. Conroy T., Galais M., Raoul J., et al. Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. J Clin Oncol 2012, 30(18 Suppl.).
77. Bang Y.-J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
78. Safran H., DiPetrillo T., Akerman P., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, {HER2} overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol 2007, 67(2):405-409.
79. A phase III trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma. Available at: [Last accessed 19.02.14]. http://www.cancer.gov/clinicaltrials/search/view?cdrid=683717%26version=HealthProfessional.
80. Zhai Y., Hui Z., Wang J., et al. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study. Dis Esophagus 2013, 26(5):503-509.
81. Waddell T., Chau I., Cunningham D., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):481-489.
82. Ohtsu A., Shah M., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29(30):3968-3976.
83. MRC ST03 Trial. Available at: [Last accessed 19.02.14]. http://www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/ST03%20Protocol%20Version%206_28Sept12_Final.pdf.